SG10201907367QA - Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor - Google Patents

Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor

Info

Publication number
SG10201907367QA
SG10201907367QA SG10201907367QA SG10201907367QA SG10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA SG 10201907367Q A SG10201907367Q A SG 10201907367QA
Authority
SG
Singapore
Prior art keywords
plp
dependent enzyme
pharmaceutical composition
cofactor
erythrocytes
Prior art date
Application number
SG10201907367QA
Inventor
Yann Godfrin
Vanessa Bourgeaux
Fabien Gay
Thomas Cortese
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201907367Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Erytech Pharma filed Critical Erytech Pharma
Publication of SG10201907367QA publication Critical patent/SG10201907367QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y206/00—Transferases transferring nitrogenous groups (2.6)
    • C12Y206/01—Transaminases (2.6.1)
    • C12Y206/01005—Tyrosine transaminase (2.6.1.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme maybe methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase. [No suitable figure]
SG10201907367QA 2014-02-12 2015-02-12 Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor SG10201907367QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1451100A FR3017299B1 (en) 2014-02-12 2014-02-12 PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR

Publications (1)

Publication Number Publication Date
SG10201907367QA true SG10201907367QA (en) 2019-09-27

Family

ID=50729647

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606264SA SG11201606264SA (en) 2014-02-12 2015-02-12 Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
SG10201907367QA SG10201907367QA (en) 2014-02-12 2015-02-12 Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201606264SA SG11201606264SA (en) 2014-02-12 2015-02-12 Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor

Country Status (17)

Country Link
US (3) US10046009B2 (en)
EP (2) EP3718562A1 (en)
JP (1) JP6563958B2 (en)
KR (1) KR102354103B1 (en)
CN (2) CN106255506B (en)
AU (2) AU2015217045B2 (en)
BR (1) BR112016017337B1 (en)
CA (1) CA2938469C (en)
CL (1) CL2016002020A1 (en)
ES (1) ES2808849T3 (en)
FR (1) FR3017299B1 (en)
IL (1) IL246941B (en)
JO (1) JO3522B1 (en)
MX (1) MX2016010235A (en)
RU (2) RU2697086C2 (en)
SG (2) SG11201606264SA (en)
WO (1) WO2015121348A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073587A2 (en) 2013-11-18 2015-05-21 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
FR3017299B1 (en) 2014-02-12 2018-05-18 Erytech Pharma PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR
ES2865825T3 (en) 2014-04-01 2021-10-18 Rubius Therapeutics Inc Methods and compositions for immunomodulation
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
HRP20220147T1 (en) 2016-01-11 2022-04-15 Rubius Therapeutics, Inc. Compositions and methods related to multimodal therapeutic cell systems for cancer indications
CN109562185A (en) 2016-06-02 2019-04-02 赛诺菲 The new conjugate of medicament and the part that albumen can be incuded in conjunction with glucose
BR112020000196A2 (en) 2017-07-07 2020-07-07 Epicentrx, Inc. compositions for parenteral administration of therapeutic agents
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US11001826B2 (en) 2017-10-19 2021-05-11 Anticancer, Inc. Orally administered composition to lower serum methionine levels and method of use
CN111433193A (en) 2017-12-01 2020-07-17 赛诺菲 Novel conjugates of agents and moieties capable of binding to glucose sensing proteins
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US20210403571A1 (en) 2018-11-15 2021-12-30 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
CN114007627A (en) 2019-04-26 2022-02-01 鲁比厄斯治疗法股份有限公司 Buffered compositions comprising enucleated erythroid cells
AU2020283752A1 (en) 2019-05-24 2021-12-23 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells
JP2023500325A (en) 2019-11-04 2023-01-05 ルビウス セラピューティクス， インコーポレイテッド Methods for generating enucleated erythroblastic cells using taurine or hypotaurine
CN115038784A (en) 2019-11-04 2022-09-09 鲁比厄斯治疗法股份有限公司 Methods of producing enucleated erythroid cells using myo-inositol
WO2021228832A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
WO2022150578A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. Methods of treating a tumor in a human subject
WO2022150569A1 (en) 2021-01-08 2022-07-14 Rubius Therapeutics, Inc. METHODS OF INCREASING NKp30-POSITIVE LYMPHOCYTES IN A SUBJECT AND USES THEREOF
TW202304482A (en) 2021-03-14 2023-02-01 美商盧比亞斯治療公司 Methods of increasing nkg2d-positive lymphocytes in a subject and uses thereof
CA3220735A1 (en) * 2021-05-21 2022-11-24 Codexis, Inc. Engineered methionine gamma lyase variants
TW202317179A (en) 2021-06-03 2023-05-01 美商盧比亞斯治療公司 Methods of treating hpv16-positive or hpv16-associated cancer in a subject
CN113481253B (en) * 2021-06-09 2022-05-24 连云港杰瑞药业有限公司 Method for preparing pyridoxal phosphate by biocatalysis
WO2023067200A1 (en) 2021-10-24 2023-04-27 Erytech Pharma Asparaginase encapsulated in red blood cells for the treatment of pancreatic cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1354204A (en) 1963-01-22 1964-03-06 Auxiliaire De L Entpr Soc Accident prevention device for loading skips, in particular for a concrete mixer
FR2529463B1 (en) * 1982-07-05 1986-01-10 Centre Nat Rech Scient METHOD AND DEVICE FOR THE ENCAPSULATION IN ERYTHROCYTES OF AT LEAST ONE BIOLOGICALLY ACTIVE SUBSTANCE, IN PARTICULAR ALLOSTERIC EFFECTORS OF HEMOGLOBIN AND ERYTHROCYTES OBTAINED THEREBY
US5631271A (en) * 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
CA2284111C (en) 1997-03-13 2009-05-19 Shionogi And Co., Ltd. Process for production of l-methionine .gamma.-lyase crystals
AU2002211512A1 (en) * 2000-10-06 2002-04-15 Millennium Pharmaceuticals, Inc. 25219, a novel human aminotransferase and uses therefor
WO2005045055A2 (en) 2003-07-31 2005-05-19 Anticancer, Inc. The use of plp with peg-rmetase in vivo for enhanced efficacy
FR2873925B1 (en) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions METHOD AND DEVICE FOR LYSE-RESCALING FOR THE INCORPORATION OF ACTIVE PRINCIPLE, IN PARTICULAR ASPARAGINASE OR INOSITOL HEXAPHOSPHATE, IN ERYTHROCYTES
FR2884717B1 (en) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions ERYTHROCYTES CONTAINING ARGININE DEIMINASE
RU2362572C2 (en) * 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Way of depression of concentration of ammonia in blood by means of ammocytes and incapsulated glutamin synthetase
FR2919804B1 (en) 2007-08-08 2010-08-27 Erytech Pharma COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
FR2925339B1 (en) 2007-12-24 2010-03-05 Erytech Pharma DRUG FOR THE TREATMENT OF PANCREATIC CANCER
CA2715379A1 (en) 2008-02-13 2009-08-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2928270B1 (en) 2008-03-10 2011-01-21 Erytech Pharma FORMULATION METHOD FOR THE PREVENTION OR TREATMENT OF BONE METASTASES AND OTHER BONE DISEASES
FR2938332B1 (en) 2008-11-07 2011-11-25 Erytech Pharma PREDICTIVE TEST FOR NEUTRALIZATION OF ASPARAGINASE ACTIVITY
CN101429506A (en) * 2008-12-15 2009-05-13 吉林大学 Fish-in-net immobilized enzyme based on rubricyte carrier
FR2944106B1 (en) 2009-04-03 2012-09-28 Erytech Pharma METHOD OF DETERMINING INOSITOL HEXAPHOSPHATE (IHP).
CA2778669C (en) 2009-10-27 2019-04-16 Erytech Pharma Composition to induce specific immune tolerance
EP2827878A1 (en) * 2012-03-21 2015-01-28 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
FR3005420B1 (en) 2013-05-07 2015-09-18 Erytech Pharma METHOD OF STABILIZING SUSPENSIONS OF ERYTHROCYTES ENCAPSULATING AN ACTIVE INGREDIENT, SUSPENSIONS OBTAINED
EP2813234A1 (en) 2013-06-11 2014-12-17 Erytech Pharma Composition of erythrocytes encapsulating phenylalanine hydroxylase and therapeutic use thereof
FR3017299B1 (en) 2014-02-12 2018-05-18 Erytech Pharma PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROCYTES ENCAPSULATING A PLP ENZYME AND ITS COFACTOR
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Also Published As

Publication number Publication date
US11458170B2 (en) 2022-10-04
WO2015121348A3 (en) 2015-10-08
AU2018201237A1 (en) 2018-03-15
JP2017506260A (en) 2017-03-02
EP3718562A1 (en) 2020-10-07
CN106255506B (en) 2020-04-14
RU2697086C2 (en) 2019-08-12
RU2016133315A (en) 2018-02-16
SG11201606264SA (en) 2016-08-30
AU2015217045A1 (en) 2016-08-18
US10046009B2 (en) 2018-08-14
IL246941B (en) 2019-09-26
US20210008114A1 (en) 2021-01-14
BR112016017337B1 (en) 2022-08-09
EP3104875B1 (en) 2020-05-06
JP6563958B2 (en) 2019-08-21
AU2018201237B2 (en) 2019-09-26
US20180344771A1 (en) 2018-12-06
FR3017299B1 (en) 2018-05-18
BR112016017337A2 (en) 2017-08-08
AU2015217045B2 (en) 2018-03-08
CN106255506A (en) 2016-12-21
CN111358941B (en) 2023-12-01
IL246941A0 (en) 2016-09-29
CA2938469A1 (en) 2015-08-20
CL2016002020A1 (en) 2017-06-23
RU2019123935A (en) 2019-10-03
RU2744659C2 (en) 2021-03-12
EP3104875A2 (en) 2016-12-21
KR20160121532A (en) 2016-10-19
RU2019123935A3 (en) 2020-03-26
CA2938469C (en) 2023-03-14
RU2016133315A3 (en) 2018-09-26
CN111358941A (en) 2020-07-03
KR102354103B1 (en) 2022-01-24
ES2808849T3 (en) 2021-03-02
US20160361361A1 (en) 2016-12-15
JO3522B1 (en) 2020-07-05
FR3017299A1 (en) 2015-08-14
MX2016010235A (en) 2016-10-28
US10780126B2 (en) 2020-09-22
WO2015121348A2 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
SG10201907367QA (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
AU2018247351B2 (en) Methods and compositions for treatment of demyelinating diseases
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
MX2013006591A (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof.
MX2018004328A (en) Stabilizing camptothecin pharmaceutical compositions.
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
WO2012174158A3 (en) Administration of benzodiazepine
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
WO2014015056A3 (en) Anti-mucus drugs and uses therefor
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
UA118474C2 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
EP3972691A4 (en) Methods and pharmaceutical compositions to treat drug overdose
PH12016502234A1 (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
MX366309B (en) Pharmaceutical composition for treating inflammation and pain.
NZ726131A (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX355719B (en) Pharmaceutical composition in the form of an oral suspension including a flavonoid fraction and xanthan gum.
MX2014014817A (en) Compounds for treating inflammation and pain.
WO2013038200A3 (en) Neurodevelopmental disorders
WO2011106378A3 (en) Oral b12 therapy
WO2019098691A3 (en) Composition and method for freeze-drying pharmaceutical composition containing anionic drug
MX2018001528A (en) Pharmaceutical composition comprising sumatripan for treating migraine.
WO2013127539A3 (en) Pharmaceutical formulation containing flupirtin